Clinical trial Recruiting at 2 sites Observational Ages 24 Weeks to 44 Weeks

Noninvasive blood pressure monitoring in newborns using a new device

Official title: Noninvasive Continuous BP Monitoring in Newborns Based on Pulsatile Signal Morphological Features Using NIRS

Run by Massachusetts General Hospital · NCT06994494 · Data updated 2026-11-12

This study is testing a new device that uses light to measure blood pressure in newborns to see if it works better than traditional methods.

More Hypotension trials

Quick facts

Study typeObservational
Ages24 Weeks to 44 Weeks
SexAll
Enrollment80 (estimated)
SponsorMassachusetts General Hospital
Academic / other
Locations2 sites (Boston, Massachusetts and 1 other locations)
StatusRecruiting
StartedApril 9, 2025
Main results expectedNovember 30, 2026
Study endsNovember 30, 2026
Registry record updatedJuly 3, 2025
Trial IDNCT06994494 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include neonates aged 24 to 44 weeks postmenstrual age who are hospitalized and at risk for unstable blood pressure.

Probably not a fit

Patients with contraindications to the FlexNIRS device placement or those with underlying congenital or genetic anomalies may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the accuracy of a novel near-infrared spectroscopy (NIRS) device in estimating blood pressure in newborns at risk for unstable blood pressure. Researchers will compare the NIRS-based estimates to traditional arterial line blood pressure readings and manual cuff measurements. The goal is to optimize and validate the FlexNIRS device for continuous and noninvasive blood pressure monitoring in neonates, which is crucial for preventing brain injury and managing various neonatal conditions. Participants will wear a small, noninvasive NIRS sensor on their forehead during the monitoring process.

Why it matters

Potential benefit: If successful, this device could provide a safer, noninvasive method for continuous blood pressure monitoring in critically ill newborns.

How similar studies have gone: While the approach of using NIRS for blood pressure monitoring is innovative, similar studies have shown promise in noninvasive monitoring techniques, but this specific application is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Neonates ≥24 \& \<44 weeks postmenstrual age
* Hospitalization in MGH or BWH newborn service units
* For A-line BP monitoring: Neonates expected to maintain A-line monitoring for at least the next 12 hours
* For non-A-line monitoring: Neonates at risk for unstable blood pressure (e.g. clinical instability or need for inotropes) and no contraindications to manual cuff BP measurements every 1 to 4 hours

Exclusion Criteria:

* Contraindication to FlexNIRS device placement on the scalp/head
* Underlying congenital/genetic anomalies

Where it's running

  • Massachusettes General Hospital
    Boston, Massachusetts, United States
    Recruiting
  • Brigham and Women's Hospital
    Boston, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.